Conference on 4th Annual Smoking Cessation (Conference Only) (Smoking Cessation)

Venue: BSG Conference Centre

Location: London, United Kingdom

Event Date/Time: Jan 25, 2010 End Date/Time: Jan 26, 2010
Report as Spam


Conference on 4th Annual Smoking Cessation (Conference Only)

Background Info
Key Speakers
• Sophie Crousse, Director - Government Affairs, Europe, GlaxoSmithKline Consumer Healthcare
• Prof Onno Van Schayck, Scientific Director - CAPHRI (Care and Public Health Research Institute), University Maastricht – Netherlands
• Dr Raafat Fahim, President and CEO, Nabi Biopharmaceuticals
• Alison Cox, Project Director, Framework Convention Alliance (Action on Smoking & Health)
• Florence Berteletti Kemp, Director, Smoke Free Partnership
• Dan Tickle, Chief Executive, No Smoking Day
• Ashok Narasimhan, President, Zenara Pharma
• Jean King, Director of Tobacco Control, Cancer Research UK
• Tim Roberts, Stop-Smoking Manager, NHS
• Dr Mira V Doig, Laboratory & QA Manager, ABS Laboratories
Smoking cessation is among the most dynamic markets within the pharma, biotech and healthcare sector, and expected to grow despite the current economic times. According to ‘Smoking Cessation 2009-2024 report’, the evolution of NRTs - including neuroreceptor modulators, enzyme inhibitors and therapeutic vaccines - will push worldwide sales of smoking cessation drugs to $1.5 billion by 2010, with majority of revenues coming from the NRTs.

Recently, the current marketed drugs have come under strict FDA regulations highlighting low safety and efficacy of existing smoking cessation products. These restraints will further strengthen the scope for robust drug pipeline and newer opportunities that will revolutionise the global smoking cessation landscape.

Following the success of our series of conferences in the UK and US, the 4th Annual Smoking Cessation conference, will discuss current challenges, unmet medical needs, scope and future treatments in the smoking cessation market. With an impressive line-up of speakers and topical themes, you will gain an international perspective on the future tobacco control activities and treatments to reduce the impact of smoking globally.

Why Attend?
By attending this conference you will gain knowledge on:
• Awareness of NRT and government/NGO efforts to tackle the tobacco use in BRIC countries
• EU perspective on price and tax measures: New proposal for the Tobacco Tax Directive
• Accurate measurements to support the assessment of nicotine addiction
• Therapeutic vaccines – revolutionising the face of anti-smoking market
• Combination therapies of smoking cessation
• Effective use of mobile technology towards a ‘Smokefree’ UK
• Monitoring smoking cessation programmes

Who should attend?
VPs, Directors, Heads and Managers of:
• Smoking Cessation
• Anti-smoking Products
• NRTs
• Tobacco Risk/Control
• Tobacco Research
• Clinical Trials
• Clinical Pharmacology
• Pharmacotherapy
• Drug Delivery
• Research & Development
• Scientific Affairs
• Primary Care
• Respiratory
• Therapeutics
• Drug Addiction
• Health Improvement
• Epidemiology
• Consumer Insights
• Outcomes Research
• Product Development
• Pricing
• Marketing/Sales
• Public Affairs/Branding/Advertising
• Regulatory Affairs

Members of:
• Pharma, Biotech & Healthcare Organisations
• Government - Department of Health, NHS PCTs
• Non-profit Organisations/Associations
• Advertising/Public Relations Bodies
• Hospitals

Day 1
Day 1, Monday 25th January 2010
09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 WHO Framework Convention on Tobacco Control: Present & future
• WHO Framework Convention: what it is and how it can be used
• Civil society and the treaty: The Framework Convention Alliance
• Development of guidelines on cessation under the treaty

Alison Cox
Project Director
Framework Convention Alliance (Action on Smoking & Health)

10:50 Expanding the global market for NRTs and making them affordable for developing countries
• Awareness of NRT and government/NGO efforts to tackle the tobacco use in developing countries
• Adapting NRT products to address the consumption of smokeless tobacco, a serious issue in the Indian subcontinent
• Significance of costs - the need to make it affordable
• BRIC market - the biggest block of tobacco users in the world

Ashok Narasimhan
Zenara Pharma

11:30 Morning refreshments

11:50 Smoking Cessation: An EU perspective
• How can community’s present and future tobacco control activities reduce demand and increase motivation to quit?
• Price and tax measures: New proposal for the Tobacco Tax Directive
• Protection from exposure to tobacco smoke: New proposal for a recommendation on smoke free
• Packaging and labelling: Revision of the Tobacco Product Directive

Florence Berteletti Kemp
Smoke Free Partnership

12.30 Accurate measurements to support the assessment of nicotine addiction
• 20 years of looking at smoking and smoking cessation
• Smoking cessation when using smokeless tobacco
• How accurate measurements can aid in smoking cessation and the development of cessation therapeutics

Dr Mira V Doig
Laboratory & QA Manager
ABS Laboratories

13.10 Monitoring smoking cessation programmes

Representative to be announced
Bedfont Scientific

13:30 Networking lunch

14.30 Nicotine vaccination: A new promising target
• Do we need new smoking cessation treatments?
• What is the additive value of nicotine vaccination?
• What could be the place of nicotine vaccination?
• Do we need combination therapies of smoking cessation?

Prof Onno Van Schayck
Scientific Director - CAPHRI (Care and Public Health Research Institute)
University Maastricht - Netherlands

15:10 Afternoon refreshments

15:30 Therapeutic vaccines – revolutionising the face of anti-smoking market
• Advantages over existing treatment therapies
• Safety & efficacy to induce irreversible addiction
• NicVax progress and next steps

Dr Raafat Fahim
President and CEO
Nabi Biopharmaceuticals

16:10 NHS evidence on smoking cessation
• Evidence for smoking cessation
• Specialist collections available to the NHS

Dr Maj Thorn
Associate Director – Sources & Head of Information, NHS Evidence
National Institute for Health and Clinical Excellence

16:50 Closing remarks from the chair

17:00 Networking Drinks
Take your discussions further and build new relationships in a relaxed and informal setting

Day 2
Day 2, Tuesday 26th January 2010,
09:30 Registration and refreshments

10:00 Opening address from the chair

Dan Tickle
Chief Executive
No Smoking Day

10:10 A comprehensive ‘National Tobacco Control’ strategy for England
• Reducing smoking rates and health inequalities caused by smoking
• Protecting children from smoking and from secondhand smoke
• Tobacco product regulation (affordability, accessibility and appeal)
• Supporting international measures and minimising industry’s influence on policy and research

Jean King
Director of Tobacco Control
Cancer Research UK

Elspeth Lee
Head of Tobacco Control
Cancer Research UK

10:50 Systems based approach to interventions in primary care
• Supporting smokers to quit as a QOF incentivised activity
• What advice do smokers need to hear?
• The importance of systems for quality stop smoking support

Alex Higgins
Smokefree Consultant
Smokefree Solutions

11:30 Morning refreshments

11:50 No Smoking Day effectiveness and smoking action programme
• Rolling out one of the biggest UK’s public health campaigns
• Understanding the smoker using social marketing techniques
• How to increase quit attempts

Dan Tickle
Chief Executive
No Smoking Day

Vishnee Sauntoo
Marketing Director
No Smoking Day

12:30 Effective use of mobile technology towards a ‘smokefree’ UK
• GP-led Campaigns
• Mobile for social Marketing Campaigns
• Supporting smokers in the process of becoming ‘Smokefree’

Sheena Macpherson
Business Development Manager
iPLATO Healthcare

Tim Roberts
Stop-Smoking Manager
NHS Hammersmith & Fulham

13:10 Networking lunch

14:10 Pharma approach: Supporting tobacco control policies with smoking cessation
• Comprehensive tobacco control policies: Prevention, protection, cessation
• Pharma outlook: The central role of smoking cessation
• How to achieve this : a partnership approach

Sophie Crousse
Director - Government Affairs, Europe
GlaxoSmithKline Consumer Healthcare

14:50 Accessibility & affordability of smoking cessation aids
Panelists from various segments of industry will discuss their views, exchange ideas on the recent developments in smoking cessation and share their experience while working on it)
Panel members will be drawn from the speakers who take part on day one or day two. If you would like to submit a question to the panel, please email it to:

15:30 Afternoon refreshments

15:50 Smoking cessation for children
• Strategies for smoking prevention and intervention amongst children
• Video Showcase: YA LUNG- “Lung: Your Atmospher, Your life”

Dr. Marcos Nascimento*
Corporate Health Strategist - Tobacco Risk Advisor, PULMAO SA
Professor - Respiratory Care, PUCPR

16:30 Presentation to be announced

17:00 Chair’s closing remarks

17:10 End of Conference

For more kindly visit

Contact us as

207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail :
Website :